149 related articles for article (PubMed ID: 29563190)
1. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors.
Aristizabal Prada ET; Heinzle V; Knösel T; Nölting S; Spöttl G; Maurer J; Spitzweg C; Angele M; Schmidt N; Beuschlein F; Stalla GK; Blaser R; Kuhn KA; Auernhammer CJ
Endocr Relat Cancer; 2018 May; 25(5):547-560. PubMed ID: 29563190
[TBL] [Abstract][Full Text] [Related]
2. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
3. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
[TBL] [Abstract][Full Text] [Related]
4. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
[TBL] [Abstract][Full Text] [Related]
6. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
7. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
[TBL] [Abstract][Full Text] [Related]
8. Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors.
Beyens M; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Endocr Relat Cancer; 2019 Mar; 26(3):R109-R130. PubMed ID: 32022503
[TBL] [Abstract][Full Text] [Related]
9. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
11. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of metformin on neuroendocrine tumor cells in vitro.
Vlotides G; Tanyeri A; Spampatti M; Zitzmann K; Chourdakis M; Spttl C; Maurer J; Nölting S; Göke B; Auernhammer CJ
Hormones (Athens); 2014; 13(4):498-508. PubMed ID: 25402373
[TBL] [Abstract][Full Text] [Related]
13. Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.
Albaugh P; Fan Y; Mi Y; Sun F; Adrian F; Li N; Jia Y; Sarkisova Y; Kreusch A; Hood T; Lu M; Liu G; Huang S; Liu Z; Loren J; Tuntland T; Karanewsky DS; Seidel HM; Molteni V
ACS Med Chem Lett; 2012 Feb; 3(2):140-5. PubMed ID: 24900443
[TBL] [Abstract][Full Text] [Related]
14. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
[TBL] [Abstract][Full Text] [Related]
15. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
17. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway.
Thress K; Macintyre T; Wang H; Whitston D; Liu ZY; Hoffmann E; Wang T; Brown JL; Webster K; Omer C; Zage PE; Zeng L; Zweidler-McKay PA
Mol Cancer Ther; 2009 Jul; 8(7):1818-27. PubMed ID: 19509272
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.
Flaum N; Valle JW; Mansoor W; McNamara MG
Future Oncol; 2016 Nov; 12(22):2561-2578. PubMed ID: 27412069
[TBL] [Abstract][Full Text] [Related]
19. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
20. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
